CoChat

Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities

Gege, Christian, Kinzel, Olaf, Steeneck, Christoph, Schulz, Andreas, Kremoser, Claus · 2014 · Current Topics in Medicinal Chemistry

The DOI matches its Crossref record.

Abstract

The Farnesoid X Receptor (FXR) was recently validated in clinical studies using the bile acid analogue Obeticholic Acid (OCA) as an attractive drug target for liver diseases such as Primary Biliary Cirrhosis (PBC) or Non-alcoholic Steatohepatitis (NASH). OCA, however, turned out to induce cholesterol- related side effects upon prolonged treatment and it shows bile acid like pharmacokinetics. The quest for synthetic non-steroidal FXR agonists with general drug likeliness and improved pharmacokinetic and - dynamic properties has started more than a decade ago: The first non-steroidal and selective FXR agonist with decent submicromolar potency, GW4064, was patented in 1998 and published in 2000. Since then, many pharmaceutical companies have taken GW4064 as a structural template for their efforts in identifying novel patentable FXR agonists with the GW-derived trisubstituted isoxazole general structure. However, so far only one compound out of these different series has made it into the early stages of clinical development: The Px-102/Px-104 from Phenex is currently tested in a phase IIa study in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). In this review we try to summarize from the patent and scientific literature the attempts to improve the GW4064 structure into different directions. Furthermore, we suggest directions for further improvements of this special class of synthetic FXR agonists which all display the typical "hammerhead"-conformation in the FXR ligand binding pocket that provides the basis for their impressive in vitro and in vivo potencies.

Overview

Integrity signals

Registry

Crossref · 10.2174/1568026614666141112094430

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 84

Metadata

Authors
Gege, C., Kinzel, O., Steeneck, C., Schulz, A., & Kremoser, C.
Affiliations
Phenex Pharmaceuticals (Germany) (DE)
Corresponding author
Kremoser, Claus
Venue
Current Topics in Medicinal Chemistry
Published
2014-11-24
Volume
14
Issue
19
Pages
2143-2158
ISSN
1568-0266 (ISSN-L)
OpenAlex
W2319858193
Cited by
69
References
0
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 1 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 10 · 2016: 11 · 2015: 4
FWCI
4.35
Type
journal article
Language
en
Open access
closed
Locations
  • Current Topics in Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
farnesoid X receptor, FXR agonists, GW4064, obeticholic acid, binding pocket, primary biliary cirrhosis, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, structure-activity optimization
MeSH terms
Receptor, Farnesoid X-Activated, Animals, Humans, Isoxazoles, Models, Molecular, Structure-Activity Relationship, Receptors, Cytoplasmic and Nuclear, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities. https://app.cochat.ai/papers/10.2174/1568026614666141112094430
The paper
Gege, C., Kinzel, O., Steeneck, C., Schulz, A., & Kremoser, C. (2014). Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026614666141112094430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.